Indian AI-powered drug discovery company Peptris has raised ₹70 crore (about $7.7 million) in a Series A round co-led by IAN Alpha Fund and Speciale Invest, with participation from Tenacity Ventures and BYT Ventures, to advance its clinical pipeline and expand its AI-driven platform.
"The use of AI for molecule discovery, which re-engineers the economics of early drug discovery by enabling faster decisions, reducing costs, and significantly accelerating go-to-market timelines, really excited us. At its core, this investment is about serving humanity better,” — Rajnish Kapur, Managing Partner, IAN Alpha Fund
🔗 https://www.techinasia.com/news/ian-alpha-fund-backs-indian-ai-drug-firm-peptris-with-7-7m-series-a
Oura Ring has introduced new capabilities enabling women to participate in AI-driven health studies, with a focus on women’s health patterns and insights backed by research initiatives.
"By having a more custom model on the back end, our advisory experience becomes that much more personalized and tailored to our female members," — Tanvi Jayaraman, Health AI, ŌURA
🔗 https://www.zdnet.com/article/oura-womens-health-ai-clinical-research-how-to-try/
Epicured Inc., a leading food-as-medicine company, has acquired Chiyo Inc., a stage-specific women’s health nutrition provider, to make clinically informed, nutrient-dense dietary support more integrated and reimbursable within women’s care pathways.
"Chiyo's dedication to clinical and culinary quality impressed me from day one [...] Our investment in Chiyo expands on our early work supporting women through our Managed Medicaid and digestive disease programs." — Richard Bennett, Co-Founder & CEO, Epicured
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved imlunestrant tosylate (Inluriyo) as a new targeted therapy for adults with locally advanced or metastatic ER-positive, HER2-negative breast cancer that has progressed after hormone therapy, expanding treatment options in this challenging indication.
“The approval of imlunestrant tosylate (Inluriyo) provides a new treatment for adults with recurrent or metastatic breast cancer after prior hormone treatment hasn’t been effective." — Julian Beach, Interim Executive Director of Healthcare Quality and Access, MHRA
🔗 https://www.nationalhealthexecutive.com/articles/mhra-approves-new-breast-cancer-treatment
MediKarma has completed the acquisition of Nanell, a digital pregnancy journey solution developed by Niterra Ventures, integrating its intellectual property and product assets to expand proactive care and support for expectant mothers within its AI-driven health platform.
“This acquisition immediately fast-tracks MediKarma’s expansion into women’s health with a solution purpose-built for the critical moments that happen between visits, this is a strategic move that strengthens value for payors and employers.” — Kris Narayan, CEO, MediKarma
